9875/3 Chronic myelogenous leukemia, BCR-ABL positive


Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive
Chronic myelogenous leukemia, t(9;22)(q34;q11)
Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive
Chronic granulocytic leukemia, t(9;22)(q34;q11)
Chronic granulocytic leukemia, BCR/ABL


Tumours of haematopoietic and lymphoid tissues
ICD-O-3 topography code: C42 and C77
ICD10: C92.1

/span>hronic myelogenous leukaemia (CML) is a myeloproliferative neoplasm that originates in an abnormal pluripotent bone marrow (BM) stem cell and is consistently associated with the BCR-ABL1 fusion gene located in the Philadelphia (Ph) chromosome 1
Click to access Pubmed
Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M (1983)
Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia.
Nature 306: 277-80

Click to access Pubmed
Melo JV, Barnes DJ (2007)
Chronic myeloid leukaemia as a model of disease evolution in human cancer.
Nat Rev Cancer 7: 441-53

Click to access Pubmed
Rowley JD (1973)
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
Nature 243: 290-3

. Although the initial major finding is neutrophilic leukocytosis, the BCR-ABL1 is found in all myeloid lineages as well as in some lymphoid cells and endothelial cells. The natural history of untreated CML is bi- or triphasic: an initial indolent chronic phase (CP) is followed by an accelerated phase (AP), a blast phase (BP) or both.